A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome

ISSN
0085-2538
Date Issued
2020
Author(s)
Tönshoff, Burkhard
Weber, Lutz T.
Pape, Lars
Latta, Kay
Fehrenbach, Henry
Lange-Sperandio, Baerbel
Hoyer, Peter
Wilkening, Frauke
DOI
10.1016/j.kint.2019.12.015